SMSouradip Mookerjee

Souradip Mookerjee

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Souradip Mookerjee has a total of 97 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Rapid Renin Angiotensin Aldosterone System inhibitor optimisation in patients with chronic kidney disease and heart failure with reduced ejection fraction using potassium binder: a randomised, double-blinded, placebo-controlled trial

    by Debasish Banerjee, Mahrukh Ali, Ella Tumelty, Daniel Murphy, Hilary Warrens, Simran Parmar, Thomas McNally, Tony Lopez, Sharirose Abat, Riny Paul, et al.

    Renin-angiotensin-aldosterone inhibitors (RAASi) improve outcomes in patients with heart failure with reduced ejection fraction (HFrEF), but their use is often limited by hyperkalaemia in chronic kidney disease (CKD) patients. This double-blind, placebo-controlled, randomised trial evaluated whether sodium zirconium cyclosilicate (SZC) enables RAASi up-titration in HFrEF patients with CKD stages 3–5 and serum potassium of 5.0–5.5 mmol/L over 14 weeks. The primary binary outcome was defined as achieving the target dose of RAAS inhibition therapy without reaching hyperkalaemia (serum potassium ≥5.6 mmol/L) over 14 weeks or otherwise. Participants ( n = 112) were randomised 1:1 to receive sodium zirconium cyclosilicate (SZC) or placebo. The per-protocol (PP) analyses included 43 out of 53 (81%) in the SZC arm and 53 out of 59 participants (90%) in the placebo arm; the intention-to-treat (ITT) analyses included all 112. At the end of the trial, 24 of 43 participants (56%) in the SZC group achieved the target RAASi dose without developing hyperkalaemia compared with 15 of 53 patients (28%) in the placebo group (PP analysis, p = 0.006, ITT analysis, p = 0.007,). Participants in the SZC group were 3 times more likely to reach the target dose without reaching potassium 5.6 mmol/L (OR = 3.16; 95% CI 1.35–7.39; p = 0.008) than in the placebo group (ITT analysis). No significant differences in adverse events between the two groups were observed. SZC appears to safely support rapid RAASi optimisation in HFrEF patients with CKD. This trial was funded by AstraZeneca via Externally Sponsored Scientific Research grant ESR-19-20174. Trial Registration: Clinicaltrials.gov NCT05004363 and EudraCT number 2020-002946-18.

  • Open Access

    Co-Design of a Digitally Enabled Habit-Formation Intervention for Community-Dwelling Older Adults with Pre-Frailty or Mild Frailty: A Mixed-Methods Feasibility Study (Preprint)

    by Souradip Mookerjee, Alex Dallman-Porter, Tricia Tay, Tori Simpson, Shuang Wu, Gianpaolo Fusari, Matthew Harrison, Kate Grailey, Jonathan James Gregory, Michael Fertleman, et al.

    BACKGROUND Frailty prevalence among older adults is rising globally, with significant implications for quality of life, healthcare costs, and economic productivity. While multicomponent lifestyle interventions can reverse frailty, existing programmes such as Vivifrail and the Otago Exercise Programme are limited by poor long-term adherence. Digital technologies combined with behavioural science principles offer a potential solution, yet few interventions have been developed with meaningful input from older adults themselves. OBJECTIVE To co-design a digitally-enabled intervention and to evaluate its feasibility, acceptability, and preliminary effects on health behaviours and frailty status in community-dwelling older adults. METHODS A mixed-methods feasibility study was conducted with 30 community-dwelling adults aged 65 and over (mean age 72.6 years; 45% men, 55% women) scoring 0-4 on the Fried Frailty Scale at enrolment. The "Healthy Habits" intervention was iteratively developed through four co-design cycles, incorporating wearable sensors (smartwatch, smart scale, sleep analyser), and a custom mobile application providing personalised feedback on seven habit domains. Participants engaged for a minimum of six weeks, with optional extended participation. Outcomes included retention, engagement metrics, changes in daily step count and sedentary time, grip strength, and frailty scores (Fried and Edmonton scales). RESULTS Retention was 97% (29/30) at six weeks, with 83% of completers electing to continue participation up to a maximum of 54 weeks. Smartwatch adherence was high (80% wear time). Among participants, 79% (22/28) demonstrated greater than 10% improvement in either daily step count or sedentary time. In the subgroup receiving the digital application (n=7), 71% increased daily steps by more than 10% within six weeks. Mean grip strength improved by 8% (p=0.013) and Edmonton Frailty Scale scores decreased by 48% (p=0.015). CONCLUSIONS A co-designed, digitally enabled intervention based on habit formation principles is feasible and acceptable to older adults, with high retention and preliminary evidence of improvements in physical activity, sedentary behaviour, and frailty markers. These findings support progression to a randomised controlled trial to evaluate efficacy. CLINICALTRIAL N/A

  • Combining long-term circuit mapping and network transcriptomics with SiR-N2c

    by Hassal Lee, Ernesto Ciabatti, Ana González-Rueda, Elena Williams, Fiona Nugent, Souradip Mookerjee, Fabio Morgese, Marco Tripodi

    An exciting frontier in circuit neuroscience lies at the intersection between neural network mapping and single-cell genomics. Monosynaptic rabies viruses provide a promising platform for the merger of circuit mapping methods with -omics approaches. However, three key limitations have hindered the extraction of physiologically meaningful gene expression profiles from rabies-mapped circuits: inherent viral cytotoxicity, high viral immunogenicity and virus-induced alteration of cellular transcriptional regulation. These factors alter the transcriptional and translational profiles of infected neurons and their neighboring cells. To overcome these limitations we applied a self-inactivating genomic modification to the less immunogenic rabies strain, CVS-N2c, to generate a self-inactivating CVS-N2c rabies virus (SiR-N2c). SiR-N2c not only eliminates undesired cytotoxic effects but also substantially reduces gene expression alterations in infected neurons and dampens the recruitment of innate and acquired immune responses, thus enabling open-ended interventions on neural networks and their genetic characterization using single-cell genomic approaches.


  • Open Access

    CRLF3 plays a key role in the final stage of platelet genesis and is a potential therapeutic target for thrombocythemia

    by Cavan Bennett, Moyra Lawrence, Jose A. Guerrero, Simon Stritt, Amie K. Waller, Yahui Yan, Richard W. Mifsud, Jose Ballester-Beltrán, Ayesha Baig, Annett Mueller, et al.

    The process of platelet production has so far been understood to be a 2-stage process: megakaryocyte maturation from hematopoietic stem cells followed by proplatelet formation, with each phase regulating the peripheral blood platelet count. Proplatelet formation releases into the bloodstream beads-on-a-string preplatelets, which undergo fission into mature platelets. For the first time, we show that preplatelet maturation is a third, tightly regulated, critical process akin to cytokinesis that regulates platelet count. We show that deficiency in cytokine receptor-like factor 3 (CRLF3) in mice leads to an isolated and sustained 25% to 48% reduction in the platelet count without any effect on other blood cell lineages. We show that Crlf3−/− preplatelets have increased microtubule stability, possibly because of increased microtubule glutamylation via the interaction of CRLF3 with key members of the Hippo pathway. Using a mouse model of JAK2 V617F essential thrombocythemia, we show that a lack of CRLF3 leads to long-term lineage-specific normalization of the platelet count. We thereby postulate that targeting CRLF3 has therapeutic potential for treatment of thrombocythemia.


  • Open Access

    Physiological effects and subjective tolerability of prone positioning in COVID-19 and healthy hypoxic challenge

    by Akhilesh Jha, Fangyue Chen, Sam Mann, Ravi Shah, Randa Abu-Youssef, Holly Pavey, Helen Lin-Jia-Qi, Josh Cara, Daniel Cunningham, Kate Fitzpatrick, et al.

    Background: Prone positioning has a beneficial role in coronavirus disease 2019 (COVID-19) patients receiving ventilation but lacks evidence in awake non-ventilated patients, with most studies being retrospective, lacking control populations and information on subjective tolerability.Methods: We conducted a prospective, single-centre study of prone positioning in awake non-ventilated patients with COVID-19 and non-COVID-19 pneumonia. The primary outcome was change in peripheral oxygenation in proneversussupine position. Secondary outcomes assessed effects on end-tidal CO2, respiratory rate, heart rate and subjective symptoms. We also recruited healthy volunteers to undergo proning during hypoxic challenge.Results: 238 hospitalised patients with pneumonia were screened; 55 were eligible with 25 COVID-19 patients and three non-COVID-19 patients agreeing to undergo proning – the latter insufficient for further analysis. 10 healthy control volunteers underwent hypoxic challenge. Patients with COVID-19 had a median age of 64 years (interquartile range 53–75). Proning led to an increase in oxygen saturation measured by pulse oximetry (SpO2) compared to supine position (difference +1.62%; p=0.003) and occurred within 10 min of proning. There were no effects on end-tidal CO2, respiratory rate or heart rate. There was an increase in subjective discomfort (p=0.003), with no difference in breathlessness. Among healthy controls undergoing hypoxic challenge, proning did not lead to a change in SpO2or subjective symptom scores.Conclusion: Identification of suitable patients with COVID-19 requiring oxygen supplementation from general ward environments for awake proning is challenging. Prone positioning leads to a small increase inSpO2within 10 min of proning though is associated with increased discomfort.


  • Open Access

    Transfer to the clinic: refining forward programming of hPSCs to megakaryocytes for platelet production in bioreactors

    by Amanda L. Evans, Amanda Dalby, Holly R. Foster, Daniel Howard, Amie K. Waller, Momal Taimoor, Moyra Lawrence, Souradip Mookerjee, Marcus Lehmann, Annie Burton, et al.

    The production of in vitro–derived platelets has great potential for transfusion medicine. Here, we build on our experience in the forward programming (FoP) of human pluripotent stem cells (hPSCs) to megakaryocytes (MKs) and address several aspects of the complex challenges to bring this technology to the bedside. We first identify clinical-grade hPSC lines that generate MKs efficiently. We design a bespoke media to maximize both production and maturity of MKs and improve platelet output. Crucially, we transition the lentiviral-based FoP of hPSCs to a nonviral inducible system. We also show how small molecules promote a definitive hematopoiesis phenotype during the differentiation process, thereby increasing the quality of the final product. Finally, we generate platelets using a bioreactor designed to reproduce the physical cues that promote platelet production in the bone marrow. We show that these platelets are able to contribute to both thrombus formation in vitro and have a hemostatic effect in thrombocytopenic mice in vivo.


  • Open Access

    In vitro-derived platelets: the challenges we will have to face to assess quality and safety

    by S. Mookerjee, H. R. Foster, A. K Waller, C. J. Ghevaert

    Platelet transfusions are given to patients in hospital who have a low blood platelet count (thrombocytopenia) either because of major bleeding (following trauma or surgery) or because the bone marrow production of platelets is impaired often due to chemotherapy, infiltration with malignant cells, fibrosis or genetic disorders. We are currently entirely reliant on blood donors as a source of platelets in transfusion medicine. However, the demand for platelets continues to rise, driven by an aging population, advances in medical procedures and ever more aggressive cancer therapies, while the supply of blood donors continues to remain static. In recent years, several groups have made major advances toward the generation of platelets in vitro for human transfusion. Recent successes include results in both generating mature human megakaryocytes as well as in developing bioreactors for extracting platelets from these megakaryocytes. Platelets made in vitro could address several issues inherent to platelets derived from blood donors – the ability to scale up/down more flexibly according to demand and therefore less precarious supply line, reduction of the risk of exposure to infectious agents and finally the possibility of engineering stem cells to reduce immunogenicity. Here we define the quality control tools and suggest measures for implementation across the field for in vitro platelet genesis, to aid collaboration between laboratories and to aid production of the burdens of proof that will eventually be required by regulators for efficacy and biosafety. We will do this firstly, by addressing the quality control of the nucleated cells used to make the platelets with a particular emphasis to safety issues and secondly, we will look at how platelet function measurement are addressed particularly in the context of platelets derived in vitro.


  • Open Access

    The integrated stress response regulates BMP signalling through effects on translation

    by Elke Malzer, Caia S. Dominicus, Joseph E. Chambers, Jennifer A. Dickens, Souradip Mookerjee, Stefan J. Marciniak

    Developmental pathways must be responsive to the environment. Phosphorylation of eIF2α enables a family of stress-sensing kinases to trigger the integrated stress response (ISR), which has pro-survival and developmental consequences. Bone morphogenetic proteins (BMPs) regulate multiple developmental processes in organisms from insects to mammals. Here we show in Drosophila that GCN2 antagonises BMP signalling through direct effects on translation and indirectly via the transcription factor crc (dATF4). Expression of a constitutively active GCN2 or loss of the eIF2α phosphatase dPPP1R15 impairs developmental BMP signalling in flies. In cells, inhibition of translation by GCN2 blocks downstream BMP signalling. Moreover, loss of d4E-BP, a target of crc, augments BMP signalling in vitro and rescues tissue development in vivo. These results identify a novel mechanism by which the ISR modulates BMP signalling during development.